Individuals with type 1 diabetes have to monitor their blood glucose levels, determine the quantity of insulin required to achieve optimal glycaemic control and administer it themselves subcutaneously, multiple times per day. To help with this process bolus calculators have been developed that suggest the appropriate dose. However these calculators do not automatically adapt to the specific circumstances of an individual and require fine-tuning of parameters, a process that often requires the input of an expert. To overcome the limitations of the traditional methods this paper proposes the use of an artificial intelligence technique, case-based reasoning, to personalise the bolus calculation. A novel aspect of our approach is the use of temporal sequences to take into account preceding events when recommending the bolus insulin doses rather than looking at events in isolation. The in silico results described in this paper show that given the initial conditions of the patient, the temporal retrieval algorithm identifies the most suitable case for reuse. Additionally through insulin-on-board adaptation and postprandial revision, the approach is able to learn and improve bolus predictions, reducing the blood glucose risk index by up to 27% after three revisions of a bolus solution.
25 February 2021 in Diabetes Technology & Therapeutics
Background: The Patient Empowerment through Predictive Personalized Decision Support (PEPPER) system provides personalized bolus advice for people with type 1 diabetes. The system incorporates an adaptive insulin recommender system (based on case-based reasoning, an artificial intelligence methodology), coupled with a safety system, which includes predictive glucose alerts and alarms, predictive low-glucose suspend, personalized carbohydrate recommendations, and dynamic bolus insulin constraint. We evaluated the safety and efficacy of the PEPPER system compared to a standard bolus calculator. Methods: This was an open-labeled multicenter randomized controlled crossover study. Following 4-week run-in, participants were randomized to PEPPER/Control or Control/PEPPER in a 1:1 ratio for 12 weeks. Participants then crossed over after a washout period. The primary end-point was percentage time in range (TIR, 3.9–10.0 mmol/L [70–180 mg/dL]). Secondary outcomes included glycemic variability, quality of life, and outcomes on the safety system and insulin recommender. Results: Fifty-four participants on multiple daily injections (MDI) or insulin pump completed the run-in period, making up the intention-to-treat analysis. Median (interquartile range) age was 41.5 (32.3–49.8) years, diabetes duration 21.0 (11.5–26.0) years, and HbA1c 61.0 (58.0–66.1) mmol/mol. No significant difference was observed for percentage TIR between the PEPPER and Control groups (62.5 [52.1–67.8] % vs. 58.4 [49.6–64.3] %, respectively, P = 0.27). For quality of life, participants reported higher perceived hypoglycemia with the PEPPER system despite no objective difference in time spent in hypoglycemia. Conclusions: The PEPPER system was safe, but did not change glycemic outcomes, compared to control. There is wide scope for integrating PEPPER into routine diabetes management for pump and MDI users. Further studies are required to confirm overall effectiveness. Clinical trial registration: ClinicalTrials.gov NCT03849755
No studies have assessed the efficacy of telemedicine using a platform for recording and adjusting insulin doses in patients with diabetes mellitus type 2 (DM2) transitioning from inpatient to outpatient care. This study aimed to assess, in a population of patients with DM2, discharged from a tertiary referral hospital, whether treatment based on the use of an mHealth application was associated with better glycemic control at the 3-month follow-up, than standard care. This open, randomized, controlled clinical trial included adult DM2 patients who were transitioning from inpatient to outpatient care. The efficacy and safety of patient management with and without mHealth was compared at the 3-month follow-up. The primary outcome was the change in the Glycosylated hemoglobin (HbA1c) levels. The secondary outcomes were the rates of hypoglycemic and hyperglycemic events and treatment satisfaction measured using the Insulin Treatment Satisfaction Questionnaire (ITSQ). In total, 86 patients (41 using mHealth) were included in the clinical trial. HbA1c levels showed a significant decrease in both groups. The mean HbA1c level was significantly lower in the mHealth group. Patients using mHealth showed decreased incidence rate ratios of hypoglycemia 3.0 mmol/L [<54 mg/dl], hypoglycemia ranging from 3.0 to 3.8 mmol/L [54 to 70 mg/dl] and severe hypoglycemia. The level of satisfaction assessed using the ITSQ was higher in the mHealth group. Using mHealth in patients with DM2 transitioning from inpatient to outpatient care improves metabolic control and may reduce the hypoglycemia rates.
: Nested (or non-uniform, or non-regular) datatypes have recursive definitions in which the type parameter changes. Their folds are restricted in power due to type constraints. Bird and Paterson introduced generalised folds for extra power, but at the cost of a loss of efficiency: folds may take more than linear time to evaluate. Hinze introduced efficient generalised folds to counter this inefficiency, but did so in a pragmatic way: he did not provide categorical or equivalent underpinnings, so did not get the associated universal properties for manipulating folds. We combine the efficiency of Hinze’s construction with the powerful reasoning tools of Bird and Paterson’s.